Fundraising FoxImmuneBridge
San Francisco, US · Founded 2022 · Delaware corporation · 10 known investors
Find your way into ImmuneBridge
Each arrow is one introduction. Sign up to fill in the first one.
Ask Bauer LeSavage to introduce you to Nina Horowitz
You →Bauer · together at ImmuneBridge →Nina
Ask Jamie Chen to introduce you to Peretz Partensky
You →Jamie · together at Sourcery →Peretz
Sign up to find every way you can get introduced to ImmuneBridge
- Your email: who you already know at ImmuneBridge, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ImmuneBridge team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
Founders & leadership
ImmuneBridge was founded in 2022 by Peretz Partensky.
Board
Investors · 10
How we know: founderlodge.com · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · funding news · tamradar.com · Not right? Tell us
__Twitter.png)
How we know: funding news · founderlodge.com · Not right? Tell us
How we know: funding news · tamradar.com · Not right? Tell us
How we know: a partner's Signal profile · funding news · founderlodge.com · Not right? Tell us
How we know: a partner's Signal profile · funding news · founderlodge.com · Not right? Tell us
How we know: funding news · tamradar.com · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$23.5M disclosed across 3 of 4 rounds · 2022–2026
- $7.7Msecond seed roundMar 2026 · 2 sources
NFX (lead), Healthspan Capital, Insight Partners, LongGame Ventures, M Ventures, One Way Ventures, Sand Hill Angels, T.Rx Capital
Source ↗
▶$5.6MraisedApr 2025 · 6 investors · BiotechnologyRule 506(b)
- Dylan MorrisDirector
- Nadiya IshnazarovaDirector
- Omri Amirav-DroryDirector
- Alicia JacksonDirector
- Stuart Alexander JacobsonExecutive Officer, Director
- Thomas FarrellDirector
- Offering amount
- $7.1M
- Amount sold
- $5.6M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$10.2MraisedJan 2023 · 15 investors · BiotechnologyRule 506(b)
- Alicia JacksonDirector
- Cheryl ZimberlinDirector
- Gregory A. BonfiglioDirector
- Peretz PartenskyExecutive Officer, Director
- Dylan MorrisDirector
- Mary Kim WarrenDirector
- Offering amount
- $14.2M
- Amount sold
- $10.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through ImmuneBridge went on to found or lead other companies.
Related companies · 7
Companies working in the same space as ImmuneBridge.
In the news
Frequently asked questions
- What does ImmuneBridge do?
- ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
- Who founded ImmuneBridge?
- ImmuneBridge was founded by Peretz Partensky in 2022.
- Who are ImmuneBridge's investors?
- ImmuneBridge's investors include M Ventures, NFX, Pioneer, Gaingels, Healthspan Capital, Insight Partners, One Way Ventures, Sand Hill Angels.
- How much funding has ImmuneBridge raised?
- ImmuneBridge has disclosed $23.5M raised across 3 of its 4 known rounds.
- Where is ImmuneBridge headquartered?
- ImmuneBridge is headquartered in San Francisco, US.